Earnings call transcript: BioCryst Q1 2026: EPS Miss, Revenue Beat

BioCryst reported Q1 2026 revenue of $156.41 million, beating estimates by 3.13%, but posted a severe EPS miss at -$2.98 versus a $0.05 forecast, which drove the stock down 6.87% premarket. ORLADEYO revenue rose 21% year over year to about $148 million, and management reiterated full-year 2026 ORLADEYO guidance of $625 million-$645 million despite a pellet manufacturing delay. The company also highlighted strong early integration of Astria Therapeutics and continued progress in navenibart and BCX17725.

Analysis

The market is treating BCRX like a clean earnings miss, but the real issue is not demand — it is capital allocation and visibility. The core franchise still appears resilient enough to support near-term revenue continuity, which matters because in rare disease, commercial durability often re-rates the whole platform; however, the Astria-related charge and higher R&D spend keep reported earnings noisy enough to suppress multiple expansion for at least 1-2 quarters.

The more interesting second-order effect is competitive: injectable HAE launches are likely to pressure the incumbent injectable leader first, while BCRX’s oral base remains comparatively sticky. That creates a temporary window where BCRX can defend share without spending aggressively, but it also means the upside from new competition is being captured elsewhere in the category, not necessarily by BCRX. If the pediatric launch is delayed only a few weeks, the impact is likely mostly timing; if it slips into late 2026, that becomes a model reset because the Street is implicitly assigning some option value to a broadening age cohort.

The contrarian angle is that investors may be overweighting the EPS miss and underweighting the strategic value of a de-risked late-stage pipeline plus a royalty-rich externalization of navenibart in Europe. The company is now positioning itself like a self-funded rare-disease platform rather than a single-asset story, and that can matter more than near-term GAAP optics if execution holds. The key catalyst set is over the next 30-120 days: pediatric supply resolution, navenibart enrollment completion, and whether management can keep OPEX discipline while advancing two clinical programs.

Key Decisions for Investors

• Trade the reaction: buy BCRX on weakness only if it reclaims the premarket gap over the next 1-3 sessions; upside is a re-rate toward prior trading range if the market concludes the EPS miss was largely non-recurring, while stop-loss should be below the post-earnings low because a delayed pediatric launch would force estimates lower.
• Pair trade: long BCRX / short a higher-multiple HAE beneficiary with less earnings durability over the next 1-2 quarters; the thesis is that BCRX’s oral franchise remains stickier than the market is pricing, while the market may be overpaying for pure launch momentum elsewhere.
• Sell near-dated downside puts only after manufacturing clarity is released; implied vol should stay elevated until the company proves the pediatric issue is a timing issue rather than a recurring supply-chain defect. Best expression is a 30-60 day put spread rather than outright short stock.
• If you want exposure to the navenibart optionality, use a call spread 6-9 months out: the catalyst is enrollment completion and de-risking of the phase III path, with asymmetric upside if the market starts assigning meaningful probability to a best-in-class injectable HAE franchise.
• Avoid chasing ATXS; the acquisition adds strategic breadth but also integration and accounting noise. The cleaner trade is BCRX itself, where the market is still pricing the story as if one bad GAAP print invalidates the underlying revenue trajectory.